COMPARATIVE ANALYSIS OF CYTOKINE PRODUCTION BY BLOOD IMMUNOCOMPETENT CELLS AND TUMOR IN DIFFERENT AGE GROUPS OF PATIENTS WITH INVASIVE DUCTAL CARCINOMA

It is known that a relationship exists between patient’s age and pathogenesis of malignant tumors associated with ability of tumor and its microenvironment to secrete cytokines that may play an important role in carcinogenesis. The aim of present study was a comparative analysis of cytokine production by peripheral blood cells and tumor samples when exposed to polyclonal activators (PA) in patients of different age groups with invasive ductal carcinoma. Peripheral blood samples of 54 women with invasive ductal carcinoma were under study. The patients were divided into the following groups: I, 40-60 years old; II, 61 year and older. Metastases into lymph nodes were revealed at the moment of study in 13 patients (42%) from group I. By contrast, only 3 of 23 (10%) patients with metastases were revealed in group II. Fisher’s ratio test showed significant differences between occurrence of metastases in lymph nodes, and patient age (p = 0.034). In both groups of patients, there was an increase of IL-6, IL-8, IL-10, IL-17, IL-18, IL-1ra, G-CSF, GM-CSF and VEGF concentrations in tumor supernates and its microenvironment, when compared with the production of cytokines by blood cells, thus indicating to high functional activity of tumor together with its microenvironment. Effect of PA led to increase of IL-2, IL-10, IL-17, IL-1β, IL-1ra, TNFα and IFNγ concentrations in blood cells supernatant which suggested their high ability to produce cytokines. In the group of patients who were 40-60 years old, the stimulatory index of PA (SIPA) for IFNγ production was several times higher than similar index in patients aged 61 years or more. Increase of SIPA for all cytokines in blood cells supernates, in comparison to SIPA of tumor supernates, could be explained by initially high levels of spontaneous cytokine production by the tumor and its microenvironment that are able to promote tumor growth. Therefore, effect of PA upon tumor tissue was not so expressed as its effect upon immunocompetent blood cells. Both tumor and microenvironment maintained high ability of IL-18 production, thus confirming its important role in carcinogenesis. In summary, these findings suggest that circulating immunocompetent cells may serve as an additional factor providing tumor progression, due to their high ability to secrete cytokines.

cytokines, supernatant, polyclonal activators, breast cancer

1. Аутеншлюс А.И., Соснина А.В., Великая Н.В., Фурсов С.А., Михайлова Е.С., Исакова Н.Б., Морозов Д.В., Лыков А.П., Вараксин Н.А. Оценка цитокинпродуцирующей функции клеток крови и пролиферативной активности опухолевых клеток при раке толстой кишки // Российский аллергологический журнал, 2011. № 4. С. 34-35. [Autenshlyus A.I., Sosnina A.V., Velikaya N.V., Fursov S.A., Mikhailova E.S., Isakova N.B., Morozov D.V., Lykov A.P., Varaksin N.V. Estimation of cytokine-producing function of blood cells and proliferative activity of tumor cells in colon cancer. Rossiyskiy allergologicheskiy zhurnal = Russian Allergological Journal, 2011, no. 4, pp. 34-35. (In Russ.)]

2. Косенок В.К., Бельская Л.В., Массард Ж., Вьюшков Д.М. Статистические особенности заболеваемости раком молочной железы в Омской области // Вопросы онкологии, 2016. Т. 62, № 4. С. 410-415. [Kosenok V.K., Belskaya L.V., Massard Zh., Viyushkov D.M. Statistical features of breast cancer incidence in the Omsk region. Voprosy oncologii = Problems in Oncology, 2016, Vol. 62, no. 4, pp. 410-415. (In Russ.)]

3. Кунц Т.А., Карпухина К.В., Михайлова Е.С., Маринкин И.О., Вараксин Н.А., Аутеншлюс А.И., Ляхович В.В. Влияние поликлональных активаторов на продукцию цитокинов клетками крови и злокачественных новообразований молочной железы // Доклады академии наук, 2016. Т. 466, № 1. С.117-119. [Kunts T.A., Marinkin I.O., Karpukhina K.V., Mikhaylova E.S., Autenshlyus A.I., Lyakhovich V.V., Varaksin N.A. Effect of polyclonal activators on cytokine production by blood cells and by malignant breast cancer cells. Doklady akademii nauk = Reports of the Academy of Sciences, 2016, Vol. 466, no. 1, pp. 117-119. (In Russ.)]

4. Соснина А.В., Великая Н.В., Вараксин Н.А., Гришаев М.П., Аутеншлюс А.И. Роль цитокинов в патогенезе злокачественных новообразований. Новосибирск, 2014. 128 с. [Sosnina A.V., Velikaya N.V., Varaksin N.A., Grishaev M.P., Autenshlus A.I. the Role of cytokines in the pathogenesis of malignant tumors]. Novosibirsk, 2014. 128 p.

5. Blaylock R.L. Cancer microenvironment, inflammation and cancer stem cells: a hypothesis for a paradigm change and new targets in cancer control. Surg. Neurol. Int., 2015, Vol. 6, p. 92.

6. Brat D.J., Bellail A.C., Van Meir E.G. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncol., 2005, Vol. 7, no. 2, pp. 122-133.

7. Conti-Freitas L.C., Foss-Freitas M.C., Mamede R.C.M., Foss N.T. Interferon-gamma and interleukin-10 production by mononuclear cells from patients with advanced head and neck cancer. Clinics, 2012, Vol. 67, no. 6, pp. 587-590.

8. Dinarello C.A. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 2011, Vol. 117, no. 14, pp. 3720-3732.

9. Duluc D., Corvaisier M., Blanchard S., Catala L., Descamps P., Gamelin E., Ponsoda S., Delneste Y., Hebbar M., Jeannin P. Interferon-gamma reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. Int. J. Cancer, 2009, Vol. 125, no. 2, pp. 367-373.

10. Eissa S.A., Zaki S.A., El-Maghraby S.M., Kadry D.Y. Importance of serum IL-18 and RANTES as markers for breast carcinoma progression. J. Egypt Natl. Canc. Inst., 2005, no. 17, pp. 51-55.

11. Fabbi M., Carbotti G., Ferrini S. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP. J. Leukoc. Biol., 2015, no. 97, pp. 665-675.

12. Hartman Z.C., Poage G.M., den Hollander P., Tsimelzon A., Hill J., Panupinthu N., Zhang Y., Mazumdar A., Hilsenbeck S.G., Mills G.B., Brown P.H. Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. Cancer Res., 2013, no. 73, pp. 3470-3480.

13. Hedrich C.M., Rauen T., Apostolidis S.A., Grammatikos A.P., Rodriguez Rodriguez N., Ioannidis C., Kyttaris V.C., Crispin J.C., Tsokos G.C. Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. PNAS, 2014, no. 111, pp. 13457-13462.

14. Huang S., Wu M., Shun C., Wang H., Lin M. Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. J. Biomed. Sci., 2004, no. 11, pp. 517-527.

15. Iyoda M., Shibata T., Kawaguchi M., Hizawa N., Yamaoka T., Kokubu F., Akizawa T. IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta. Am. J. Physiol. Renal Physiol., 2010, Vol. 298, no. 3, pp. F779-787.

16. Jain R.K., Fukumura D., Duda D.G. From the guest editors: role of tumor microenvironment in tumor progression and treatment response: A 30 Years’ Journey. Cancer Journal, 2015, Vol. 21, no. 4, pp. 235-236.

17. Lindahl G., Saarinen N., Abrahamsson A., Dabrosin C. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell–derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. Cancer Res., 2011. Vol. 71, no. 1, pp. 51-60.

18. Ma J., Ren Z., Ma Y., Xiao W. Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy. J. Biol. Chem., 2009, Vol. 284, no. 50, pp. 34600-34606.

19. Man Y., Stojadinovic A., Mason J., Avital I., Bilchik A., Bruecher B., Protic M., Nissan A., Izadjoo M., Zhang X., Jewett A. Tumor-infiltrating immune cells promoting tumor invasion and metastasis: existing theories. J. Cancer, 2013, Vol. 4, no. 1, pp. 84-95.

20. Marco M., Fortin C., Fulop T. Membrane-type matrix metalloproteinases: key mediators of leukocyte function. J. Leukoc. Biol., 2013, no. 94, pp. 237-246.

21. McClintock J.Y., Wagner E.M. Role of IL-6 in systemic angiogenesis of the lung. J. Appl. Physiol., 2005, Vol. 99, no. 3, pp. 861-866.

22. Murakami Y., Watari K., Shibata T., Uba M. Ureshino H., Kawahara A., Abe H., Izumi H., Mukaida N., Kuwano M., Ono M. N-myc downstream-regulated gene 1 promotes tumor inflammatoryangiogenesis through JNK activation and autocrine loop of interleukin-1α by human gastric cancer cells. J. Biol. Chem., 2013, no. 288, pp. 25025-25037.

23. Odenthal J., Takes R., Friedl P. Plasticity of tumor cell invasion: governance by growth factors andcytokines. Carcinogenesis, 2016, Vol. 37, pp. 1117-1128.

24. Park S., Cheon S., Cho D. The dual effects of interleukin-18 in tumor progression. Cell. Mol. Immunol., 2007, Vol. 4, no. 5, pp. 329-335.

25. Picon-Ruiz M., Pan C., Drews-Elger K., Jang K., Besser A.H., Zhao D., Morata-Tarifa C., Kim M., Ince T.A., Azzam D.J., Wander S.A., Wang B., Ergonul B., Datar R.H., Cote R.J., Howard G.A., El-Ashry D., Torné-Poyatos P. Marchal J.A., Slingerland J.M. Interactions between adipocytes and breast cancer cells stimulatecytokine production and drive Src/Sox2/miR-302b–mediated malignant progression. Cancer Res., 2016, no. 76, pp. 491-504.

26. Queen M.M., Ryan R.E., Holzer R.G., Keller-Peck C.R., Jorcyk C.L. Breast cancer cells stimulate neutrophils to produce oncostatin M: potential implications for tumor progression. Cancer Res., 2005, no. 65, pp. 8896-8904.

27. Shida Y., Igawa T., Hakariya T., Sakai H., Kanetake H. p38MAPK activation is involved in androgenindependent proliferation of human prostate cancer cells by regulating IL-6 secretion. Biochem. Biophys. Res. Commun., 2007, Vol. 353, no. 3, pp. 744-749.

28. Smith D.A., Kiba A., Zong Y., Witte O.N. Interleukin-6 and Oncostatin-M synergize with the PI3K/AKT Pathway to promote aggressive prostate malignancy in mouse and human tissues. Mol. Cancer Res., 2013, no. 11, pp. 1159-1165.

29. Society A.C. Breast Cancer Facts and Figures 2013–2014. American Cancer Society, Inc., Atlanta, 2013. https://old.cancer.org/acs/groups/content@research/documents/document/acspc-042725.pdf

30. Sun W., Liu D.B., Li W.W., Zhang L.L., Long G.X., Wang J.F., Mei Q., Hu G.Q. Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9. Int. J. Oncol., 2014, no. 44, pp. 1551-1560.

31. Tarrio M.L., Lee S.-H, Fragoso M.F., Sun H-W., Kanno Y., O’Shea J.J., Biron C.A. Proliferation conditions promote intrinsic changes in NK cells for an IL-10 response. J. Immunol., 2014, no. 193, pp. 354-363.

32. Triozzi P.L., Aldrich W., Singh A. Effects of interleukin-1 receptor antagonist on tumor stroma in experimental uveal melanoma. Invest. Ophthalmol. Vis. Sci., 2011, Vol. 52, no. 8, pp. 5529-5535.

33. Tsuji-Takayama K., Suzuki M., Yamamoto M., Harashima A., Okochi A., Otani T., Inoue T., Sugimoto A., Toraya T., Takeuchi M., Yamasaki F., Nakamura S., Kibata M. The production of IL-10 by human regulatory T cells is enhanced by IL-2 through a STAT5-responsive intronic enhancer in the IL-10 locus. J. Immunol., 2008, Vol. 181, no. 6, pp. 3897-3905.

34. Yang Y., Cheon S., Jung M.K., Song S.B., Kim D., Kim H.J., Park H., Bang S.I., Cho D. Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of thep38 MAPK pathway. Biochem. Biophys. Res. Commun., 2015, Vol. 10, no. 459 (3), pp. 379-386.